An interventional study of Dynamic Strength Training and Isometric Strength Training in Hypertension and Elderly (People Aged 65 or More), sponsored by Raphael Mendes Ritti Dias. Recruiting at 1 site in Brazil. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Raphael Mendes Ritti Dias · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.
Among the 209 studies in Hypertension with a site in Brazil, this one is the 107th largest by planned enrollment of the 189 interventional ones that give a count, is one of 8 that started in 2026, is one of 112 with no phase, reaches primary completion later than 20 of the 32 other live ones, and was the 203rd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:
University of Nove de Julho · Sites in Brazil
Ages 18–65
AstraZeneca · Sites in Brazil
Ages 18+
Instituto Dante Pazzanese de Cardiologia · Sites in Brazil
Ages 18+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–75
Alnylam Pharmaceuticals · Sites in Brazil, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 40 · Phase 4 31
First in 1999; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 80 across the 189 interventional studies, 127 across the 18 observational. Of the 136 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 209 have an industry lead sponsor. The 10 most frequent:
Raphael Mendes Ritti Dias is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Raphael Mendes Ritti Dias has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypertension with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07361276AstraZenecaObservational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System | 2026-11-30 |
| NCT06105775University of Sao PauloInorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies | 2026-12 |
| NCT06169241National Institute of Cardiology, Laranjeiras, BrazilEffect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients | 2026-12 |
| NCT06917131Universidade Federal FluminenseRoyal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension | 2026-12-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 209 studies in Hypertension with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This feasibility study aims to evaluate the effects of dynamic strength training and isometric strength training on cardiovascular health indicators, mental health, and neuromuscular fitness in older adults with hypertension. Participants will be randomly assigned to one of the two training modalities and will complete supervised exercise sessions throughout the intervention period. The study will provide preliminary evidence regarding the safety, acceptability, and potential impact of each training modality on health outcomes in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
The subjects randomized to this group will perform two supervised dynamic strength training sessions per week for 6 weeks, each session lasting approximately 30 minutes.
Behavioral: Dynamic Strength Training
The subjects randomized to this group will perform two supervised isometric strength training sessions per week for 6 weeks, each session lasting approximately 30 minutes.
Behavioral: Isometric Strength Training
No supervised training will be provided. Participants in this group will not receive any exercise intervention during the 6-week study period, but they will be stimulated to be active.
Behavioral: No supervised intervention Control
The experimental group will perform dynamic strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group movements, initially 2 sets of 15 repetitions (Borg 4-6), progressing to 3 sets of 10 repetitions (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.
The experimental group will perform isometric strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group contractions, initially 2 sets of 60 seconds (Borg 4-6), progressing to 3 sets of 40 seconds (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.
This group serves as a control and will not perform any structured exercise program.
Recruitment rate
Proportion of enrolled participants relative to the total number of eligible individuals contacted. Reported as a percentage.
Time frame: Baseline and 6 weeks
Adherence to training sessions
Percentage of completed training sessions relative to the total number of planned sessions over the 6-week intervention period.
Time frame: During 6 weeks
Retention rate
Proportion of participants who complete the full 6-week intervention
Time frame: During 6 weeks
Fidelity to exercise protocol
Percentage of exercises performed according to the prescribed protocol parameters, including load, repetitions, and time under tension.
Time frame: Duiring 6 weeks
Acceptability of the intervention
Acceptability assessed through a structured satisfaction questionnaire, scored from 0 to 10, administered at the end of the 6-week intervention
Time frame: During 6 weeks
Occurrence of adverse events
Number of intervention-related adverse events, classified as mild, moderate, or severe
Time frame: During 6 weeks
Change from baseline in Clinical resting blood pressure at 6 weeks
Systolic and diastolic blood pressure measured with automatic device (HEM-742, Omron Healthcare, Japan) in seated position, average of last two of three readings, in millimeters of mercury.
Time frame: Baseline and 6 weeks
Change from baseline in Home blood pressure monitoring at 6 weeks
Seven-day home monitoring with automatic device (Omron Healthcare, Japan), two readings morning and evening in duplicate; average of valid readings, in millimeters of mercury
Time frame: Baseline and 6 weeks
Change from baseline in Flow-mediated dilation at 6 weeks
Brachial and femoral artery vasodilation assessed by ultrasonography with spectral Doppler (Cannon Xario, Japan); calculated as percentage change from baseline
Time frame: Baseline and 6 weeks
Change from baseline in Standard deviation of normal R-R intervals at 6 weeks
Standard deviation of normal R-R intervals will be assessed using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).
Time frame: Baseline and 6 weeks
Change from baseline in Arterial stiffness at 6 weeks
Carotid-femoral pulse wave velocity measured by applanation tonometry (SphygmoCor, AtCor Medical, Australia), calculated as distance/time in meters per second
Time frame: Baseline and 6 weeks
Change from baseline in Depressive symptoms at 6 weeks
Geriatric Depression Scale (GDS-15), 15 items, scored 0-15, higher score = worse symptoms
Time frame: Baseline and 6 weeks
Change from baseline in Anxiety symptoms at 6 weeks
Generalized Anxiety Disorder questionnaire (GAD-7), 7 items, scored 0-21, higher score = worse symptoms
Time frame: Baseline and 6 weeks
Change from baseline in Six-Minute Walk Test distance at 6 weeks
Distance walked in meters during the six-minute walk test performed in a 30-meter corridor.
Time frame: Baseline and 6 weeks
Change from baseline in Root mean square of successive differences between R-R intervals at 6 weeks
Root mean square of successive differences between R-R intervals will be measured using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).
Time frame: Baseline to 6 weeks
Change from baseline in Proportion of successive R-R intervals differing by more than 50 milliseconds at 6 weeks
Proportion of successive R-R intervals differing by more than 50 milliseconds will be measured using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).
Time frame: Baseline to 6 weeks.
Change from baseline in Low-frequency spectral power at 6 weeks
Low-frequency spectral power will be assessed using the Polar V800 (Polar Electro, Finland) and expressed in ms².
Time frame: Baseline to 6 weeks.
Change from baseline in high-frequency power at 6 weeks
high-frequency power High-frequency component measured with Polar V800 (Polar Electro, Finland), expressed in ms².
Time frame: Baseline to 6 weeks.
Change from baseline in Low-frequency to high-frequency ratio at 6 weeks
Low-frequency to high-frequency ratio measured with Polar V800 (Polar Electro, Finland).
Time frame: Baseline to 6 weeks.
Change from baseline in Timed Up and Go Time at 6 weeks
time in seconds to stand from a chair, walk 3 meters, turn, return, and sit down.
Time frame: Baseline and 6 weeks.
Change from baseline in 30-second Chair stand repetitions at 6 weeks
number of full stands from a seated position completed in 30seconds.
Time frame: Baseline and 6 weeks.
Change from baseline in handgrip strength at 6 weeks
maximum voluntary isometric handgrip strength measured using handheld dynamometer instrutherm DM-90 (Brazil), expressed in kilogram-force (kgf).
Time frame: Baseline and 6 weeks.
Change from baseline in isometric knee extensor strength at 6 weeks
Maximum isometric knee extensor strength measured at 90º knee angle using horizontal leg press, expressed in kilogram-force (kgf).
Time frame: Baseline and 6 weeks.
Plan to share: Yes — Data will be anonymized and shared after the completion of the study and publication of the main results
Supporting information: Study protocol
Time frame: Data will be shared adter the publication of the main trial
Access criteria: Will be avaliable in open repositories
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 15 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Raphael Mendes Ritti Dias